Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5502333 | Journal of Geriatric Oncology | 2017 | 5 Pages |
Abstract
SBRT for early-stage NSCLC is the accepted standard of care in medically inoperable patients, though in many very elderly patients, dose is either de-intensified or withheld for concern of toxicity in the setting of advanced age and competing risks. In this study of our very elderly (â¥Â 80 years old) early-stage NSCLC patients, we highlight both the extremely high efficacy and tolerability (zero grade 2 or above toxicities) associated with definitive intent SBRT.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Paul Kreinbrink, Philip Blumenfeld, George Tolekidis, Neilayan Sen, David Sher, Gaurav Marwaha,